$BJDX

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, Mass. October 13, 2026 — Bluejay Diagnostics, In

Bluejay Diagnostics (NASDAQ:BJDX) completed a manufacturing site for its Symphony™ sepsis test cartridges ahead of the October 23, 2026 deadline. The site, established under its agreement with Toray, is part of a strategy to diversify manufacturing with SanyoSeiko in Japan and ALURIS in the U.S. This milestone reduces commercialization risk as the company advances toward regulatory submission.

Bluejay Diagnostics (BJDX) reported preliminary SYMON-II data from 777 patients, showing ~18% 28-day mortality, to evaluate its Symphony IL-6 test for sepsis. The test is not FDA-cleared, and analyses are ongoing.

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Bluejay Diagnostics (BJDX) reported Q2 2026 results with cash and cash equivalents rising to $9.6M from $5.2M at Dec. 31, 2025, an 84% increase, driven by $7.7M net cash from financing including $7.6M from a June private placement. The company completed pivotal enrolment of 750 patients in SYMON-II to support a planned FDA 510(k) for its Symphony IL-6 test.

Bluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.

Bluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.

HRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029420901ex10-1.htm BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO. 1 THERETO Exhibit 10.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO.1 THERETO Section 1. Establishment and Purpose. 1.1 The Board of Directors (the “Boa